Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Innovate Biopharmaceuticals Inc (INNT)

Innovate Biopharmaceuticals Inc (INNT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,582
  • Shares Outstanding, K 35,884
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,160 K
  • 60-Month Beta -2.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.05
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.41
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/12/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.11
  • Growth Rate Est. (year over year) -18.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.75 +17.35%
on 11/14/19
1.11 -20.71%
on 10/16/19
-0.22 (-19.99%)
since 10/15/19
3-Month
0.75 +17.35%
on 11/14/19
1.29 -31.78%
on 09/17/19
+0.13 (+17.35%)
since 08/15/19
52-Week
0.73 +20.89%
on 08/15/19
4.32 -79.63%
on 03/18/19
-2.08 (-70.27%)
since 11/15/18

Most Recent Stories

More News
RDD Pharma Enters into Non-Binding Letter of Intent to Acquire Naia Rare Diseases, Strengthening Gastroenterology Orphan Disease Pipeline

RDD Pharma, Ltd. ("RDD"), a company focused on orphan and innovative therapies for gastrointestinal disorders entered into a non-binding letter of intent ("LOI") to acquire Naia Rare Diseases ("Naia"),...

INNT : 0.88 (+8.13%)
Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases

Deep Clinical-Stage Pipeline Combined With World-Class Leadership Team

INNT : 0.88 (+8.13%)
BDSI : 6.15 (-1.28%)
Innovate Biopharmaceuticals, Inc. Announces First Patient Dosed in the First Phase 3 Clinical Trial for Patients with Celiac Disease

CeD LA 3001 trial doses first patient in historic Phase 3 celiac disease trial

INNT : 0.88 (+8.13%)
Innovate Biopharmaceuticals Reports Second Quarter 2019 Results and Corporate Updates

Company is exploring potential strategic opportunities and non-dilutive sources of capital, and partnerships

INNT : 0.88 (+8.13%)
Innovate Biopharmaceuticals Announces Corporate Update and Expected Date for Second Quarter Earnings Release

Innovate undertakes succession planning for a chief executive officer

INNT : 0.88 (+8.13%)
Innovate Biopharmaceuticals Expands Its Management team with the Addition of Ed Sitar as Its Chief Financial Officer

Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced the appointment...

CGIX : 2.49 (-9.45%)
INNT : 0.88 (+8.13%)
Innovate Biopharmaceuticals Announces the Start of the First Phase 3 Clinical Trial in Celiac Disease

Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, announced the start of the first...

INNT : 0.88 (+8.13%)
Innovate Biopharmaceuticals Announces Presentation of Three Posters Focusing on the Molecular Biology and Pharmacology of Larazotide at the 2019 Digestive Disease Week Conference in San Diego

Analyst Meeting to be held at 4:30pm ET today to discuss NASH data and provide clinical updates

INNT : 0.88 (+8.13%)
Innovate Biopharma Announces Analyst Event on Monday, May 20, 2019, in San Diego

Innovate Biopharmaceuticals, Inc. ("Innovate") (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for immuno-inflammatory disease, announced that it plans to...

INNT : 0.88 (+8.13%)
Innovate Biopharmaceuticals Announces Closing of $8.7 Million Registered Direct Offering

Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) today announced the closing of its previously announced registered direct offering of 4,318,272 shares of common stock at a purchase price of $2.025 per...

INNT : 0.88 (+8.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade INNT with:

Business Summary

Innovate Biopharmaceuticals, Inc. is a clinical stage biotechnology company. It focused on developing novel medicines for autoimmune/ inflammatory disease. The company's pipeline includes drug candidates for celiac disease, an unmet need, and ulcerative colitis. Its products includes INN-202 for the...

See More

Key Turning Points

2nd Resistance Point 0.96
1st Resistance Point 0.92
Last Price 0.88
1st Support Level 0.82
2nd Support Level 0.76

See More

52-Week High 4.32
Fibonacci 61.8% 2.95
Fibonacci 50% 2.52
Fibonacci 38.2% 2.10
Last Price 0.88
52-Week Low 0.73

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar